Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $4,131,326.78 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 195,427 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $21.14, for a total transaction of $4,131,326.78. Following the sale, the director owned 975,931 shares of the company’s stock, valued at approximately $20,631,181.34. The trade was a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $23.07 on Friday. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The firm has a market cap of $3.81 billion, a PE ratio of -7.16 and a beta of 1.06. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The company’s fifty day simple moving average is $18.63 and its two-hundred day simple moving average is $18.16.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the prior year, the business earned ($1.05) earnings per share. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Sanford C. Bernstein upped their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Finally, TD Cowen initiated coverage on Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. increased its stake in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after acquiring an additional 14,727,667 shares during the last quarter. Vanguard Group Inc. increased its stake in Dyne Therapeutics by 14.9% in the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after purchasing an additional 1,455,151 shares during the period. State Street Corp increased its stake in Dyne Therapeutics by 27.0% in the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after buying an additional 1,423,828 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Dyne Therapeutics by 45.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after acquiring an additional 1,618,000 shares in the last quarter. Finally, Orbis Allan Gray Ltd bought a new stake in Dyne Therapeutics during the 4th quarter valued at $93,926,000. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.